The gap between trial data and clinical practice - An analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation

Cerebrovascular Diseases

Volumn 36, Issue 2, 2013, Pages 115-119

  Pfeilschifter, Waltraud ^a,b   Luger, Sebastian ^a   Brunkhorst, Robert ^a   Lindhoff Last, Edelgard ^b   Foerch, Christian ^a  

^a Department of Neurology ^*  (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anticoagulant therapy; Cardioembolic stroke; Intracranial hemorrhage; Warfarin associated intracerebral hemorrhage

Indexed keywords

AMIODARONE; ANTITHROMBOCYTIC AGENT; DABIGATRAN; RIVAROXABAN; VERAPAMIL;

ANTICOAGULANT THERAPY; AORTIC INTRAMURAL HEMATOMA; ARTICLE; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CONJUNCTIVAL HEMORRHAGE; CREATININE CLEARANCE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; EPIDURAL HEMATOMA; EPISTAXIS; GASTROINTESTINAL SYMPTOM; HEART TAMPONADE; HEMARTHROSIS; HEMATOMA; HUMAN; LUNG HEMORRHAGE; MEDICATION COMPLIANCE; MEDICATION ERROR; PATIENT COMPLIANCE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK FACTOR; SENESCENCE; SEVERE RENAL IMPAIRMENT; SPLEEN HEMATOMA; SUBCONJUNCTIVAL HEMORRHAGE; TREATMENT DURATION; UNDERWEIGHT;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84885573991     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000352062     Document Type: Article

References (13)

1. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RELY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
5. Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C: Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. Int J Cardiol, E-pub ahead of print
6. ClinicalTrials.gov Identifier of Phase IIIII: NCT01468701. https://www.gloria-af.com/ public/about-regDesign.html (accessed Dec 17, 2012)
7. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG: International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163: 13-19
8. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED: Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011; 162: 606-612
9. Harper P, Young L, Merriman E: Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-866
10. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL, Tomlin ME: Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012; 18: 139-146
11. Harder S: Renal profiles of anticoagulants. J Clin Pharmacol 2012; 52: 964-975
12. Southworth MR, Reichman ME, Unger EF: Dabigatran and postmarketing reports of bleeding. N Engl J Med, E-pub ahead of print
13. Weber JCP: Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res 1984; 6: 1-7.